Lifitegrast-d4-1
Product Specifications
UNSPSC Description
Lifitegrast-d4-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease[1][2].
Target Antigen
Integrin; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Cytoskeleton;Others
Field of Research
Inflammation/Immunology
Smiles
O=C(N[C@H](C(O)=O)CC1=CC=CC(S(C)(=O)=O)=C1)C2=C(Cl)C3=C(C([2H])([2H])N(C(C4=CC=C5C=COC5=C4)=O)C([2H])([2H])C3)C=C2Cl
Molecular Weight
619.51
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Perez VL, et al. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. Ocul Surf. 2016 Apr;14(2):207-15.|[3]Sun Y, et al. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther. 2013 May;29(4):395-402.|[4]Rao VR, et al. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin(STZ) model of diabetic retinopathy (DR). Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5198-204.
Shipping Conditions
Room temperature
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
